Analyser av Klaria Pharma

Klaria Pharma Q2: Defining Chapter Approaches - Redeye

Redeye leaves a research update following Klaria Pharma’s recently published Q2 2024 report.

Klaria Pharma: Sumatriptan alginate film receive market approval - Redeye

Redeye leaves a comment following today’s encouraging news that Klaria has received market authorization in key European markets for its lea...

Redeye • 14 Aug 09:11

Klaria Pharma Q1: Crucial period ahead - Redeye

Redeye leaves a research update following Klaria Pharma’s recently published Q1 2024 report.

Redeye • 16 May 16:18

Klaria Pharma Q4: Eyes on the prize - Redeye

Redeye leaves a research update following Klaria Pharma’s Q4 2023 report published earlier today.

Redeye • 01 Mar 15:03

Klaria Pharma: Secures short-term financing - Redeye

Redeye leaves a comment on Klaria’s announcement of a signed bridge loan agreement with a term of two years.

Redeye • 20 Dec 2023 12:42

Klaria Pharma: Mot ett nytt år med en ny VD - Penser

Kvartalet i korthet Klaria Pharma stängde böcker för det tredje kvartalet i fredags och rapporten innehöll inga överraskningar.

Penser • 27 Nov 2023 10:27

Klaria Pharma Q3 2023: Take-off is on the horizon - Redeye

Redeye leaves a research update following Klaria Pharma’s Q3 2023 report.

Redeye • 27 Nov 2023 08:15

Klaria Pharma: Change of CEO - Redeye

Redeye leaves a comment on yesterday’s news that Jesper Wiklund is stepping down as the CEO of Klaria Pharma and that the board has decided ...

Redeye • 26 Oct 2023 09:50

Klaria Pharma Q2: Focus on sealing the deal - Redeye

Redeye comments on Klaria Pharma’s Q2 2023 report. Despite the recent rights issue at the end of 2022, which generated SEK59.

Redeye • 29 Aug 2023 11:32

Klaria Pharma Holding Q1 2023: No headache just yet - Redeye

Redeye comments on Klaria Pharma’s Q1 2023 report. The company reports continued validation of its epinephrine alginate film.

Redeye • 16 May 2023 07:46

Klaria Pharma: The Swedish Financial Supervisory Authority initiates an investigation - Redeye

Redeye comments on The Swedish Financial Supervisory Authority´s decision to initiate an investigation of Klaria Pharma.

Redeye • 29 Mar 2023 07:54

Klaria Pharma Holding: A punch in the face for migraines - Redeye

Redeye initiates coverage of Klaria Pharma Holding AB, a Swedish biotech company, utilising its transmucoadhesive drug delivery technology p...

Redeye • 27 Mar 2023 08:50

Börskollen

För dig med koll på börsen